Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial

详细信息    查看全文

• 作者：Anna Maria Di Giacomo ; Paolo A Ascierto ; Lorenzo Pilla ; Mario Santinami ; Pier Francesco Ferrucci ; Diana Giannarelli ; Antonella Marasco ; Licia Rivoltini ; Ester Simeone ; Stefania VL Nicoletti ; Ester Fonsatti ; Diego Annesi ; Paola Queirolo ; Aless ; ro Testori ; Ruggero Ridolfi ; Giorgio Parmiani ; Michele Maio
• 刊名：Lancet Oncology
• 出版年：2012
• 出版时间：September, 2012
• 年：2012
• 卷：13
• 期：9
• 页码：879-886
• 全文大小：176 K

文摘

| Figures/TablesFigures/Tables | ReferencesReferences

Summary

Background

Ipilimumab improves survival of patients with metastatic melanoma, many of whom develop brain metastases. Chemotherapy-induced release of tumour antigens might amplify ipilimumab's antitumour activity. We aimed to investigate the efficacy and safety of ipilimumab plus fotemustine in patients with metastatic melanoma with or without asymptomatic brain metastases.

Methods

In our open-label, single-arm phase 2 trial, we enrolled patients 18 years or older with measurable, locally advanced, unresectable stage III or stage IV melanoma between July 6, 2010, and April 14, 2011. Eligible patients had a life expectancy of 16 weeks or more and an Eastern Cooperative Oncology Group performance status of 1 or less, and could have received a maximum of one previous line of chemotherapy. Participants received induction treatment of 10 mg/kg intravenous ipilimumab every 3 weeks to a total of four doses, and 100 mg/m² intravenous fotemustine weekly for 3 weeks and then every 3 weeks from week 9 to week 24. Patients with a confirmed clinical response were eligible for maintenance treatment from week 24, with ipilimumab every 12 weeks and fotemustine every 3 weeks. The primary endpoint was the proportion of patients with immune-related disease control as established with immune-related response criteria. Analyses were done per protocol. This trial is registered with EudraCT, number 2010-019356-50, and with , number .

Findings

86 patients were eligible for treatment, of whom 20 had asymptomatic brain metastases at baseline. 40 patients in the study population achieved disease control (46¡¤5 % , 95 % CI 35¡¤7-57¡¤6), as did ten with brain metastases (50¡¤0 % , 27¡¤2-72¡¤8). 47 patients (55 % ) had grade 3 or 4 treatment-related adverse events, of which the most common was myelotoxicity (thrombocytopenia in 21 [24 % ] patients and neutropenia in 16 [19 % ]). The most common grade 3 or 4 immune-related adverse events were hepatic: 21 patients (24 % ) had grade 3 or 4 increases in concentrations of alanine aminotransferase or aspartate aminotransferase.

Interpretation

The combination of ipilimumab plus fotemustine has clinical activity in patients with metastatic melanoma, including those with brain metastases.

Funding

Bristol-Myers Squibb.